2022年諾貝爾獎得主Carolyn Bertozzi教授擔任育世博公司首席科學顧問

育世博研發異體細胞新藥 致力改善未滿足之癌症醫療需求

育世博與馬偕紀念醫院簽訂廣泛性細胞新藥合作開發合作備忘錄(MOU)，強化台灣創新細胞療法研發動能

育世博（Acepodia）與藥明巨諾（JW Therapeutics）宣布不行使合作協議中的選擇權

育世博獲得1億美元D輪融資，推進首創抗體細胞連結（ACC）平臺技術之異體現成型細胞新藥

育世博ACE1831 Gamma Delta T 細胞新藥完成首位病人給藥

育世博獲臺灣TFDA同意進行ACE1831細胞療法的臨床試驗

Acepodia to Present Preclinical Data on its Gamma Delta T cell Therapy Candidate, ACE1831, at 2022 SITC Annual Meeting

PR Newswire

Acepodia Congratulates Laureates of the 2022 Nobel Prize in Chemistry and Shares the Excitement to Translate Click Chemistry into a New Class of Investigational Therapies

PR Newswire

Acepodia Announces FDA Clearance of IND Application for ACE1831, an Anti-CD20 Armed Allogeneic gamma delta T-cell Therapy Candidate to Treat Patients with non-Hodgkin's Lymphoma

PR Newswire

Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapies

GlobeNewswire

Acepodia Presents Preclinical Data on its gamma delta T cell Therapy Candidate ACE1831 at 2022 AACR Meeting